<p>Adalimumab is a tumor necrosis factor (TNF) blocker indicated for treatment of:</p>

<ul>
	<li><strong>Rheumatoid Arthritis (RA)</strong>: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA</li>
	<li><strong>Juvenile Idiopathic Arthritis (JIA)</strong>: Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older</li>
	<li><strong>Psoriatic Arthritis (PsA)</strong>: Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA</li>
	<li><strong>Ankylosing Spondylitis (AS)</strong>: Reducing signs and symptoms in adult patients with active AS</li>
	<li><strong>Adult Crohn&rsquo;s Disease (CD)</strong>: Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn&rsquo;s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab</li>
	<li><strong>Pediatric Crohn&rsquo;s Disease</strong>: Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn&rsquo;s disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate</li>
	<li><strong>Ulcerative Colitis (UC)</strong>: Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of Adalimumab has not been established in patients who have lost response to or were intolerant to TNF blockers</li>
	<li><strong>Plaque Psoriasis (Ps)</strong>: The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate</li>
	<li><strong>Hidradenitis Suppurative (HS)</strong>: The treatment of moderate to severe hidradenitis suppurativa</li>
</ul>